The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Greetings, and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not ...

Dan Dischner (Senior Vice President of Human Resources & Corporate Communication) said Q1 reflected “a return to growth, driven primarily by contributions from recent product launches,” while the ...

Amphastar’s Q1 2026 EPS of $0.42 missed forecasts by 41.9%. Revenue increased marginally to $171.2 million, up 0.4% from Q1 2025. Stock price rose slightly by 0.54% despite the earnings miss. Pricing ...

Explore the science behind today’s most popular skincare actives, from niacinamide to retinoids, and discover what truly works, what remains unproven, and how evidence-based choices are shaping the ...

Spiriva (tiotropium bromide) is an anticholinergic medication that relaxes airway muscles to ease breathing in chronic obstructive pulmonary disease (COPD) and asthma. It’s meant for long-term daily ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported first-quarter 2026 net revenues of approximately $171.2 million, up slightly from $170.5 million in the prior-year period, as recently launched ...

Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, prompting a negative market reaction. Management ...

Spiriva (tiotropium) is a brand-name medication to help manage chronic obstructive pulmonary disease (COPD) and asthma. It comes as Spiriva HandiHaler (powder capsule) and Spiriva Respimat (liquid ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...